Abstract:Chronic myeloid leukemia (CML) results from malignant transformation of hematopoietic stem cells induced by the BCR-ABL oncogene. Transformation from chronic to blastic phase is the lethal step in CML. Leukemic stem cells (LSCs) are the basic reason for blastic transformation. It has been shown that Wnt/β-catenin signaling contributes to the self-renewal capacity and proliferation of LSCs in CML. However, the role of Wnt/β-catenin signaling in blastic transformation of CML is still obscure. Here, we explored the relationship between BCR-ABL and β-catenin signaling in vitro and in vivo. We found that BCR-ABL stimulated β-catenin via activation of PI3K/AKT signaling in blastic phase CML cells. Inhibition of the kinase activity of BCR-ABL, PI3K, or AKT decreased the level of β-catenin in both K562 cells and a CML mouse model and suppressed the transcription of downstream target genes (c-myc and cyclin D1). In addition, inhibition of the BCR-ABL/PI3K/AKT pathway delayed the disease progression in the CML mouse model. To further explore the role of β-catenin in the self-renewal and survival of CML LSCs, we established a secondary transplantation CML mouse model. Our data revealed that inhibition of the BCR-ABL/PI3K/AKT pathway reduced the tumor-initiating ability of K562 cells, decreased leukemia cell infiltration into peripheral blood and bone marrow, and prolonged the survival of mice. In conclusion, our data indicate a close relationship between β-catenin and BCR-ABL/PI3K/AKT in blastic phase CML. β-Catenin inhibition may be of therapeutic value by targeting LSCs in combination with a tyrosine kinase inhibitor, which may delay blastic transformation of CML.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the mechanism of the transformation of chronic myeloid leukemia (CML) from the chronic phase to the acute phase, especially the role of the Wnt/β - catenin signaling pathway in this transformation process. Specifically, the author explored the relationship between BCR - ABL and β - catenin and its mechanism of action in CML acute - phase cells. Through in - vivo and in - vitro experiments, the study investigated how BCR - ABL stimulates the expression of β - catenin by activating the PI3K/AKT signaling pathway and further affects the transcription of downstream target genes, such as c - myc and cyclin D1. In addition, the study also evaluated the impact of inhibiting the BCR - ABL/PI3K/AKT pathway on the disease progression of CML mouse models and whether this inhibition can reduce the expression of β - catenin, thereby reducing the self - renewal ability and tumor - forming ability of CML cells. ### Main findings of the paper: 1. **BCR - ABL activates β - catenin**: - In CML acute - phase patients and cell lines, the expression level of BCR - ABL is significantly higher than that in the chronic phase, and the expression of β - catenin also increases significantly. - Through real - time RT - PCR and Western blot analysis, the high - expression of BCR - ABL and β - catenin in CML acute - phase patients and cell lines was confirmed. 2. **Inhibiting BCR - ABL, PI3K and AKT reduces the expression of β - catenin**: - After treating K562 cells with imatinib (IM), LY294002 (PI3K inhibitor) and AKTi IV (AKT inhibitor), the expression of β - catenin decreased significantly, and its distribution in the nucleus and cytoplasm also decreased. - Further experiments proved that these inhibitors reduce the protein stability of β - catenin by promoting its degradation. 3. **Inhibiting the BCR - ABL/PI3K/AKT pathway reduces the transcription of β - catenin target genes**: - After inhibiting the BCR - ABL/PI3K/AKT pathway, the expressions of c - myc and cyclin D1 decreased significantly, indicating that the activity of β - catenin was inhibited. 4. **Inhibiting the BCR - ABL/PI3K/AKT pathway delays the development of CML**: - In the CML mouse model, after treatment with IM, LY294002 and AKTi IV, the body weight loss, white blood cell count and spleen enlargement of the mice were significantly reduced, and the survival time was prolonged. - The results of immunofluorescence and histochemical staining showed that inhibiting the BCR - ABL/PI3K/AKT pathway significantly reduced the expression of β - catenin in the peripheral blood, bone marrow, lungs and spleen of mice. 5. **Inhibiting the BCR - ABL/PI3K/AKT pathway reduces the tumor - initiating ability of CML cells**: - The secondary transplantation experiment showed that inhibiting the BCR - ABL/PI3K/AKT pathway significantly reduced the tumor - initiating ability of K562 cells, decreased the infiltration of leukemia cells in the peripheral blood and bone marrow, and prolonged the survival time of mice. ### Conclusion: This study revealed that BCR - ABL enhances the stability of β - catenin by activating the PI3K/AKT signaling pathway, thereby promoting the development of CML acute - phase. Inhibiting the BCR - ABL/PI3K/AKT pathway can not only reduce the expression of β - catenin, but also reduce the self - renewal ability and tumor - forming ability of CML cells, thereby delaying the acute - phase transformation of CML. These findings provide a theoretical basis for the development of new treatment strategies for CML acute - phase.

Potential role of Wnt/β-catenin signaling in blastic transformation of chronic myeloid leukemia: cross talk between β-catenin and BCR-ABL

Chemoresistant Leukemia-Initiating Cell Expansion is Inhibited by Targeting Oncogenic Self-Renewal

The molecular mechanisms underlying BCR/ABL degradation in chronic myeloid leukemia cells promoted by Beclin1-mediated autophagy.

Aberrant Activation of CaMKIIγ Accelerates Chronic Myeloid Leukemia Blast Crisis.

Expression of Β-Catenin in Patients with Chronic Myeloid Leukemia

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

The role of RAS effectors in BCR/ABL induced chronic myelogenous leukemia

A Long Noncoding RNA Critically Regulates Bcr-Abl-mediated Cellular Transformation by Acting As a Competitive Endogenous RNA

Dynamic Observations of Beta-Catenin in Chronic Myeloid Leukemia and Its Relationship with Cytogenetic Response

Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia

PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation

The Blk Pathway Functions As a Tumor Suppressor in Chronic Myeloid Leukemia Stem Cells

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia

The Molecular Mechanism of Chronic Myelogenous Leukemia and Its Therapeutic Implications: Studies in A Murine Model

The Role Played by Wnt/β-Catenin Signaling Pathway in Acute Lymphoblastic Leukemia

BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy

Abstract 280: Aberrant β-catenin signaling from the bone marrow niche leads to transformation of IDH1/2 -mutant hematopoietic stem cells and compromises response to IDH1/2 inhibitors

Progress of the BCR-ABL and Src family kinases interactions leading CML to imatinib-resistance

Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML

Imatinib and Bortezomib Induce the Expression and Distribution of Anaphase-Promoting Complex Adaptor Protein Cdh1 in Blast Crisis of Chronic Myeloid Leukemia.

c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model